Background: The selection of the surgical approach for chronic pancreatitis (CP) is determined by various factors including inflammatory location, presence of pancreatic duct dilatation, or possibility of cancer. Total pancreatectomy (TP), with or without islet cell autotransplantation, is considered for patients with refractory CP after the failure of other surgical treatments. Considering the increasing incidence of CP requiring surgical treatment, the number of cases in which TP is performed after previous surgical treatment is expected to increase.
View Article and Find Full Text PDFLocomotive Syndrome (LS) is defined by decreased walking and standing abilities due to musculoskeletal issues. Early diagnosis is vital as LS can be reversed with appropriate intervention. Although diagnosing LS using standardized charts is straightforward, the labor-intensive and time-consuming nature of the process limits its widespread implementation.
View Article and Find Full Text PDFIncidence of type I allergies, such as hay fever, is continuously increasing in developed countries, including Japan. Type I allergies are triggered by chemical mediators, such as histamine, which are released via immunoglobulin E (IgE)-mediated mast cell degranulation. Therefore, medications inhibiting the synthesis, release, and receptor binding of these mediators are commonly used to manage type I allergy symptoms.
View Article and Find Full Text PDFBackground: In China, transarterial chemoembolization (TACE) and systemic therapy are the primary treatment for patients with advanced hepatocellular carcinoma (HCC). Hepatic arterial infusion chemotherapy (HAIC) is more effective than TACE in treating large HCC (largest diameter ≥7 cm) without macrovascular invasion or extrahepatic spread. Additionally, HAIC in combination with camrelizumab and apatinib has shown promising efficacy and safety in the Barcelona Clinic Liver Cancer stage C (BCLC-C) HCC.
View Article and Find Full Text PDFRecent advances in systemic therapy for hepatocellular carcinoma (HCC) have led to debates about the feasibility of combination therapies, such as systemic therapy combined with surgery or transarterial chemoembolization, for patients with advanced HCC. However, a lack of consensus on the oncological resectability criteria has hindered discussions of "conversion therapy" and the optimal management in patients with HCC. To address this issue, the Japan Liver Cancer Association (JLCA) and the Japanese Society of Hepato-Biliary-Pancreatic Surgery (JSHBPS) established a working group and discussed the concept of borderline resectable HCC.
View Article and Find Full Text PDF